Search
Close this search box.

Biogen’s ‘pick and choose’ strategy in immunology leads to $1B HI-Bio takeout

ARTICLE | Deals

Continuing diversity push under Viehbacher, Biogen obtains two programs spun out from MorphoSys, backed by Arch, Monograph, Jeito and others

By Paul Bonanos, Director of Biopharma Intelligence

May 22, 2024 4:50 PM UTC

Biogen’s acquisition of HI-Bio, its second 10-figure M&A deal since the arrival of Christopher Viehbacher as CEO in 2022, will further diversify the company’s pipeline in immunology and rare diseases as part of a continuing push to reshape the organization.

Biogen Inc. (NASDAQ:BIIB) is paying $1.15 billion up front to purchase the South San Francisco company formally known as Human Immunology Biosciences Inc., a privately held start-up that in 2022 acquired rights to programs spun out from MorphoSys AG (Xetra:MOR; NASDAQ:MOR), which Novartis AG (SIX:NOVN; NYSE:NVS) is acquiring for €2.7 billion ($2.9 billion)…